DE69834024T2 - Tetracycline verbindungen zur behandlung von spezifischen krebsarten - Google Patents

Tetracycline verbindungen zur behandlung von spezifischen krebsarten Download PDF

Info

Publication number
DE69834024T2
DE69834024T2 DE69834024T DE69834024T DE69834024T2 DE 69834024 T2 DE69834024 T2 DE 69834024T2 DE 69834024 T DE69834024 T DE 69834024T DE 69834024 T DE69834024 T DE 69834024T DE 69834024 T2 DE69834024 T2 DE 69834024T2
Authority
DE
Germany
Prior art keywords
cmt
dimethylamino
tetracycline
cancer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69834024T
Other languages
German (de)
English (en)
Other versions
DE69834024D1 (de
Inventor
M. Lorne Smithtown GOLUB
F. Thomas Port Jefferson McNAMARA
S. Nungavaram Smithtown RAMAMURTHY
Hsi-Ming Setauket LEE
Sanford Stony Brook SIMON
L. Balakrishna Miami LOKESHWAR
G. Marie Fort Lauderdale SELZER
L. Normal Miami BLOCK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Research Foundation of the State University of New York
Original Assignee
University of Miami
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami, Research Foundation of the State University of New York filed Critical University of Miami
Application granted granted Critical
Publication of DE69834024D1 publication Critical patent/DE69834024D1/de
Publication of DE69834024T2 publication Critical patent/DE69834024T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69834024T 1997-01-15 1998-01-15 Tetracycline verbindungen zur behandlung von spezifischen krebsarten Expired - Lifetime DE69834024T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US783655 1997-01-15
US08/783,655 US5837696A (en) 1997-01-15 1997-01-15 Method of inhibiting cancer growth
PCT/US1998/000332 WO1998031224A1 (en) 1997-01-15 1998-01-15 Method of inhibiting cancer growth

Publications (2)

Publication Number Publication Date
DE69834024D1 DE69834024D1 (de) 2006-05-18
DE69834024T2 true DE69834024T2 (de) 2006-12-07

Family

ID=25130005

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69834024T Expired - Lifetime DE69834024T2 (de) 1997-01-15 1998-01-15 Tetracycline verbindungen zur behandlung von spezifischen krebsarten

Country Status (11)

Country Link
US (2) US5837696A (enExample)
EP (1) EP0971585B1 (enExample)
JP (1) JP4428727B2 (enExample)
KR (1) KR20000070212A (enExample)
AT (1) ATE321452T1 (enExample)
AU (1) AU729886B2 (enExample)
CA (1) CA2277865C (enExample)
DE (1) DE69834024T2 (enExample)
ES (1) ES2262221T3 (enExample)
PT (1) PT971585E (enExample)
WO (1) WO1998031224A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837696A (en) * 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
US6429204B1 (en) 1997-01-15 2002-08-06 University Of Miami Method of inhibiting cancer growth
DK1041991T3 (da) * 1997-12-19 2008-07-28 Univ New York Ikke-antibakterielle tetracycliner til behandling af multipel sklerose
US6277061B1 (en) * 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6015804A (en) * 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) * 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
WO2000038715A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and radiation in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6984619B1 (en) * 1999-03-19 2006-01-10 Arch Development Corporation Method for protection against tumor metastasis formation
DE10032256C2 (de) * 2000-07-03 2003-06-05 Infineon Technologies Ag Chip-ID-Register-Anordnung
CA2447008A1 (en) * 2001-04-05 2002-10-24 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
EP1408987B1 (en) 2001-07-13 2013-04-10 Paratek Pharmaceuticals, Inc. Tetracycline compounds having target therapeutic activities
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
WO2003030819A2 (en) * 2001-10-05 2003-04-17 Tetragenex Pharmaceuticals, Inc. Tetracycline derivatives and methods of use thereof
PE20030701A1 (es) * 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
EP2311797A1 (en) 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
JP2005526754A (ja) 2002-03-08 2005-09-08 パラテック ファーマシューティカルズ インコーポレイテッド アミノメチル置換されたテトラサイクリン化合物
EP1503981A4 (en) 2002-03-21 2007-08-15 Paratek Pharm Innc SUBSTITUTED TETRACYCLINE COMPOUNDS
WO2003092629A2 (en) * 2002-05-06 2003-11-13 Collagenex Pharmaceuticals, Inc. Methods of simultaneously treating mucositis and fungal infection
EP1505961A4 (en) * 2002-05-20 2009-09-02 Collagenex Pharm Inc METHOD FOR TREATING ALLERGIC REACTIONS
WO2004006850A2 (en) 2002-07-12 2004-01-22 Paratek Pharmaceuticals, Inc 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS
JP4686189B2 (ja) * 2002-10-24 2011-05-18 パラテック ファーマシューティカルズ インコーポレイテッド Ｒｎａを調節するための置換テトラサイクリン化合物の使用方法
CA2521885C (en) * 2003-04-07 2013-06-25 Shire Laboratories, Inc. Once daily formulations of tetracyclines
JP4738333B2 (ja) 2003-07-09 2011-08-03 パラテック ファーマシューティカルズ インコーポレイテッド ９−アミノメチルテトラサイクリン化合物のプロドラッグ
WO2005009943A2 (en) 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
EP2332904A3 (en) * 2004-01-15 2012-04-11 Paratek Pharmaceuticals, Inc. Derivatives of tetracycline compounds
WO2006047756A2 (en) 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
JP2008518025A (ja) 2004-10-25 2008-05-29 パラテック ファーマシューティカルズ インコーポレイテッド ４−アミノテトラサイクリンおよびその使用の方法
CA2616224A1 (en) * 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
PL2120963T3 (pl) 2006-12-21 2019-05-31 Paratek Pharm Innc Podstawione związki tetracyklinowe do leczenia zaburzeń zapalnych skóry
IL270446B2 (en) * 2006-12-21 2023-10-01 Paratek Pharm Innc A tetracycline compound, a pharmaceutical preparation containing the tetracycline compound, and the tetracycline compound or the pharmaceutical preparation for the treatment of the tetracycline-responsive condition
EP2144870A2 (en) * 2007-04-27 2010-01-20 Paratek Pharmaceuticals, Inc. Methods for synthesizing and purifying aminoalkyl tetracycline compounds
WO2009009042A1 (en) * 2007-07-06 2009-01-15 Paratek Pharmaceuticals, Inc. Methods for synthesizing substituted tetracycline compounds
TWI585071B (zh) 2008-05-19 2017-06-01 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
HUE026562T2 (hu) 2008-08-08 2016-06-28 Tetraphase Pharmaceuticals Inc C7-fluor-helyettesített tetraciklin vegyületek
CN102459153A (zh) 2009-05-08 2012-05-16 四相制药公司 四环素类化合物
EP2470500B1 (en) 2009-08-28 2017-10-04 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
US20120329761A1 (en) * 2010-03-10 2012-12-27 University Health Network Use of tigecycline for treatment of cancer
WO2011123536A1 (en) 2010-03-31 2011-10-06 Tetraphase Pharmaceuticals, Inc. Polycyclic tetracycline compounds
TR201902057T4 (tr) 2012-08-31 2019-03-21 Tetraphase Pharmaceuticals Inc Tetrasiklin bileşikleri.
CA2898113C (en) * 2013-01-14 2022-05-31 Health Clinics Limited Combination cancer therapeutics and uses thereof
MA46567A (fr) 2016-10-19 2019-08-28 Tetraphase Pharmaceuticals Inc Formes cristallines de l'éravacycline
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン：癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
WO2020097450A1 (en) 2018-11-09 2020-05-14 Tetraphase Pharmaceuticals, Inc. Polymorphic forms of a compound and uses thereof
CN115006411A (zh) * 2022-07-26 2022-09-06 中南大学湘雅医院 依拉环素类化合物的应用、药物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3016587B2 (ja) * 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5308839A (en) * 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
AU1411992A (en) * 1991-01-15 1992-08-27 Robert A Bok A composition containing a tetracycline and use for inhibiting angiogenesis
US5668122A (en) * 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
US5563130A (en) * 1994-12-13 1996-10-08 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5567693A (en) * 1994-12-13 1996-10-22 American Cyanamid Company Method for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5574026A (en) * 1994-12-13 1996-11-12 American Cyanamid Company Methods for inhibiting angiogenesis proliferation of endothelial or tumor cells and tumor growth
US5837696A (en) * 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth

Also Published As

Publication number Publication date
ES2262221T3 (es) 2006-11-16
ATE321452T1 (de) 2006-04-15
WO1998031224A1 (en) 1998-07-23
JP4428727B2 (ja) 2010-03-10
AU729886B2 (en) 2001-02-15
AU5910498A (en) 1998-08-07
EP0971585B1 (en) 2006-03-29
KR20000070212A (ko) 2000-11-25
DE69834024D1 (de) 2006-05-18
CA2277865A1 (en) 1998-07-23
JP2001508794A (ja) 2001-07-03
EP0971585A4 (en) 2001-01-24
PT971585E (pt) 2006-08-31
US5837696A (en) 1998-11-17
US6100248A (en) 2000-08-08
CA2277865C (en) 2009-06-02
EP0971585A1 (en) 2000-01-19

Similar Documents

Publication Publication Date Title
AU729886B2 (en) Method of inhibiting cancer growth
DE69829748T2 (de) Hemmung der serine proteinase mittels hydrophoben tetracyclins
DE69929810T2 (de) Verwendung von tetracyclinderivaten zur steigerung der interleukin-10 produktion
DE69924268T2 (de) Kombination von bisphosphonat und tetracyclin
DE69734661T2 (de) Foerderung der wundheilung durch chemisch modifizierte tetracycline
DE3686956T2 (de) Nichtantibakterielle tetracyclinzusammensetzungen mit anticollagenolytischen eigenschaften.
DE69001429T2 (de) Zusammensetzung mit gehalt an einem nichtsteroiden entzuendungshemmenden mittel und einem nichtbakterizidwirksamen tetracyclin.
DE69327788T2 (de) Pharmazeutische zusammenstezungen zur hemmung von tumoren in verbindung mit prostaten adenokarzinom magenkrebs und brustkrebs
DE69014141T2 (de) Verwendung von Benzimidazol-Derivaten als antibakterielle Mittel.
DE60218443T2 (de) Jasmonate enthaltende therapeutische zusammensetzungen für die behandlung von krebs
DE69026620T2 (de) Anti-tumor-zubereitung enthaltend interleukin-2 und histamin, analoge dazu oder h2-rezeptor-agonisten
US6429204B1 (en) Method of inhibiting cancer growth
EP1079837A1 (en) Method of inhibiting membrane-type matrix metalloproteinase
DE69615984T2 (de) Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen
DE60131464T2 (de) Verwendung von rhein oder seinen derivaten als matrix metalloproteinase inhibitoren
DE69427130T2 (de) Ssi tyrphostine und pharmazeutische zusammensetzungen
EP0864579B1 (de) Wismutsalze von Antibiotika der Moenomycin-Gruppe, Verfahren zu ihrer Herstellung, ihre Verwendung und solche Salze enthaltende Arzneimittel
DE69809928T2 (de) Tizoxanide und nitazoxanide enthaltende pharmazeutische zusammensetzungen
DE10008159B4 (de) Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen Salze als Antikrebsmittel
DE69713570T2 (de) Verfahren zum abtöten neoplastischer zellen mittels piperazin-oxiran derivaten
EP0655249A1 (de) Moenomycin als Arzneimittel zur Behandlung von Magengeschwüren
EP0817623B1 (de) Arzneistoffe zur selektiven bekämpfung von tumorgewebe
DE2824610C2 (de) Arzneimittelgemisch aus einer Penicillansäure und aus einem Penicillin oder Cephalosporin
WO1998041204A1 (de) Ascorbinsäure als adjuvans in der chemo- und strahlentherapie von malignomen
DE3785953T2 (de) Bakterientötende Gemische.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition